RESEARCH-USE BIOSIMILAR ANTIBODY
Burfiralimab
Monoclonal antibody · IgG4
Burfiralimab (hzVSF-v13) is a monoclonal IgG4 antibody against vimentin expressed on the surface of virus-infected cells, with broad-spectrum antiviral activity and anti-inflammatory effects against virus-induced inflammation. Burfiralimab can be used in severe COVID-19 studies.
TARGETVimentin
YMonoclonal antibody
CATALOGSC-BS-698
CATALOG NUMBERSC-BS-698
MOLECULAR WEIGHTApprox. 144.6 kDa
PRODUCT FORMATMonoclonal antibody
PRODUCT OVERVIEW
A research-use configuration for comparative antibody studies
Burfiralimab (hzVSF-v13) is a monoclonal IgG4 antibody against vimentin expressed on the surface of virus-infected cells, with broad-spectrum antiviral activity and anti-inflammatory effects against virus-induced inflammation. Burfiralimab can be used in severe COVID-19 studies.
Burfiralimab is a recombinant research-use antibody directed against Vimentin.